Ventana announces collaboration to develop companion diagnostics for ImmunoGen's targeted anticancer agents

30-Oct-2014 - USA

Ventana Medical Systems, Inc. announced it has entered into an agreement with ImmunoGen, Inc. to collaborate on the development of biomarker assays and a companion diagnostic immunohistochemistry (IHC) test for one or more of ImmunoGen's product candidates. Under this agreement, the companies have created an initial test for folate receptor alpha (FRa, also known as folate receptor 1, or FOL1) that is being used in early trials of IMGN853, ImmunoGen's FRa-targeting antibody-drug conjugate (ADC). Cancers that highly express FRa include epithelial ovarian cancer, endometrial cancer, and types of non-small cell lung cancers (NSCLC).

The goal of the collaboration is to leverage Ventana's expertise in companion diagnostic development, from prototyping through regulatory approval and commercialization, to identify specific patient populations for ImmunoGen's bio-target directed therapies.

Other news from the department business & finance

More news from our other portals

So close that even
molecules turn red...